18F-氟化钠PET/CT诊断前列腺癌骨转移的观察者一致性与准确性
本研究评估了18F-NaF PET/CT在前列腺癌骨转移检测中的观察者间一致性。研究纳入4项前瞻性试验中的219例患者,两名经验丰富的观察者独立评估,结果显示患者水平一致性几乎完美(三分类未加权κ=0.83±0.05,二分类κ=0.91±0.07),病灶水平93.6%患者一致,诊断性能令人满意。
要点
- 18F-NaF PET/CT在前列腺癌骨转移诊断中观察者间一致性极高。
- 患者水平三分类未加权κ=0.83±0.05,二分类κ=0.91±0.07。
- 病灶水平205例(93.6%)患者病灶数量和位置一致。
核心结论
- 18F-NaF PET/CT检测前列腺癌骨转移的观察者间一致性在患者和病灶水平均非常高,诊断性能令人满意,是可靠的诊断工具。
研究设计与样本
- 回顾性分析4项近期前瞻性试验中219例前列腺癌患者的18F-NaF PET/CT扫描。
- 两名经验丰富的观察者独立评估,采用三分类(M0、可疑、M1)和二分类(M0/M1)量表。
- 病灶不超过10个的患者记录病灶位置和数量,采用敏感性分析处理可疑病灶。
主要发现
- 219例患者中,129例用于原发分期,67例用于生化复发,23例用于转移性去势抵抗性前列腺癌。
- 患者水平一致性几乎完美:三分类未加权κ=0.83±0.05,线性加权κ=0.90±0.06,二分类κ=0.91±0.07。
- 病灶水平(二分类)205例(93.6%)患者病灶数量和位置一致,其余14例中13例数量不一致、1例位置不一致。
- 219例中211例最终诊断为骨转移。
- 敏感性范围0.86–0.92,特异性0.83–0.97,阳性预测值0.70–0.93,阴性预测值0.94–0.96。
关键数值与推荐
- 三分类量表:无骨转移(M0)、可疑骨转移、骨转移存在(M1)。
- 二分类量表:M0/M1。
- 敏感性分析中可疑病灶分别按M0和M1处理。
临床怎么用
- 18F-NaF PET/CT可作为前列腺癌骨转移诊断的可靠工具,观察者间一致性高。
- 可疑病灶的处理方式影响诊断性能,需在报告中规范描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Our aim was to evaluate the interobserver agreement in 18F-sodium fluoride (NaF) PET/CT for the detection of bone metastases in patients with prostate cancer (PCa). Methods:18F-NaF PET/CT scans were retrieved from all patients who participated in 4 recent prospective trials. Two experienced observers independently evaluated the 18F-NaF PET/CT scans on a patient level using a 3-category scale (no bone metastases [M0], equivocal for bone metastases, and bone metastases present [M1]) and on a dichotomous scale (M0/M1). In patients with no more than 10 lesions, the location and number of lesions were recorded. On a patient level, the diagnostic performance was calculated using a sensitivity analysis, in which equivocal lesions were handled as M0 as well as M1. Results:18F-NaF PET/CT scans from 219 patients with PCa were included, of whom 129 patients were scanned for primary staging, 67 for biochemical recurrence, and 23 for metastatic castration-resistant PCa. Agreement between the observers was almost perfect on a patient level (3-category unweighted κ = 0.83 ± 0.05, linear weighted κ = 0.90 ± 0.06, and dichotomous κ = 0.91 ± 0.07). On a lesion level (dichotomous scale), the observers agreed on the number and location of bone metastases in 205 (93.6%) patients. In the remaining 14 patients, the readers disagreed on the number of lesions in 13 patients and the location of bone metastases in 1 patient. A final diagnosis of bone metastases was made for 211 of 219 patients. The sensitivity ranged from 0.86 to 0.92, specificity from 0.83 to 0.97, positive predictive value from 0.70 to 0.93, and negative predictive value from 0.94 to 0.96. Conclusion: The interobserver agreement on 18F-NaF PET/CT for the detection of bone metastases in patients with PCa was very high among trained observers, both on a patient level and on a lesion level. Moreover, the diagnostic performance of 18F-NaF PET/CT was satisfactory, rendering 18F-NaF PET/CT a robust tool in the diagnostic armamentarium.
引用
- Zacho HD, Fonager RF, Nielsen JB, et al. Observer Agreement and Accuracy of 18F-Sodium Fluoride PET/CT in the Diagnosis of Bone Metastases in Prostate Cancer. J Nucl Med. 2019. PMID: 31481577. doi:10.2967/jnumed.119.232686
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。